Linneo Health will now have access to Phytocontrol Group’s clinical analysis capabilities, and the agreement will enable both businesses to progress new developments and collaborations within the medical cannabis sector.
Through this collaboration, Madrid-based Linneo Health, along with Phytocontrol, will exclusively develop enhanced methods for pesticide and active materials analyses that will further Linneo Health’s global reach and support entry into new medicinal cannabis markets, including Israel.
The companies have stated that the agreement has huge potential, and will allow Linneo Health to accelerate its growth and progress the development of new cannabinoid profiles or changes in the matrix, along with facilitating Phytocontrol’s first move into the medicinal cannabis sector.
Read more: Linneo Health expands medical cannabis offering
CEO of Linneo Health, Don Bellamy, said: “As experts in our relative fields, this collaboration utilises both Linneo Health’s expertise in the medicinal cannabis sector and Phytocontrol’s leading clinical analysis capabilities.
“The work we will be doing with Phytocontrol will enable us to expand our reach, ensuring that we can meet the necessary requirements for entry into non-European markets, such as Israel. We’re excited about the potential of this collaboration and look forward to working closely with the Phytocontrol team going forward.”
Read more: Linneo Health receives EU-GMP Part I licence
Linneo Health currently operates a state-of-the-art, Good Manufacturing Practice (GMP) certified, quality control laboratory enabling the microbial and physical-chemical analysis of its dried flower and cannabis extracts to ensure the highest pharmaceutical grade manufacturing standards are achieved.
Regulations governing the research, cultivation, processing and distribution of medicinal cannabis in Israel are some of the strictest in the world and the demonstration of Linneo Health’s product meeting these standards illustrates the company’s commitment to quality. Israel’s medicinal cannabis market was estimated to be worth EU264 million in 20211, making it the second largest medicinal cannabis market in the world outside of the US, and the largest medicinal market in the world per head of population.
Mikael Bresson, CEO of Phytocontrol, added: “We’re delighted to be collaborating with Linneo Health in a partnership that not only provides us with a port of entry into the Iberian market, but also marks our first venture into the medicinal cannabis sector.
“We share Linneo’s belief in the commitment to quality in everything we do, and we look forward to the mutual benefits that this collaboration will bring to both our organisations.”